EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
04 Apr 2022
04 Apr 2022
Historique:
received:
19
01
2022
accepted:
18
03
2022
revised:
10
03
2022
entrez:
5
4
2022
pubmed:
6
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Neuroblastoma (NB) accounts for 15% of cancer-related deaths in childhood despite considerable therapeutic improvements. While several risk factors, including MYCN amplification and alterations in RAS and p53 pathway genes, have been defined in NB, the clinical outcome is very variable and difficult to predict. Since genes of the mechanistic target of rapamycin (mTOR) pathway are upregulated in MYCN-amplified NB, we aimed to define the predictive value of the mTOR substrate-encoding gene eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) expression in NB patients. Using publicly available data sets, we found that EIF4EBP1 mRNA expression is positively correlated with MYCN expression and elevated in stage 4 and high-risk NB patients. In addition, high EIF4EBP1 mRNA expression is associated with reduced overall and event-free survival in the entire group of NB patients in three cohorts, as well as in stage 4 and high-risk patients. This was confirmed by monitoring the clinical value of 4EBP1 protein expression, which revealed that high levels of 4EBP1 are significantly associated with prognostically unfavorable NB histology. Finally, functional analyses revealed that EIF4EBP1 expression is transcriptionally controlled by MYCN binding to the EIF4EBP1 promoter in NB cells. Our data highlight that EIF4EBP1 is a direct transcriptional target of MYCN whose high expression is associated with poor prognosis in NB patients. Therefore, EIF4EBP1 may serve to better stratify patients with NB.
Identifiants
pubmed: 35379801
doi: 10.1038/s41420-022-00963-0
pii: 10.1038/s41420-022-00963-0
pmc: PMC8980029
doi:
Types de publication
Journal Article
Langues
eng
Pagination
157Informations de copyright
© 2022. The Author(s).
Références
Breast Cancer Res. 2013;15(5):R96
pubmed: 24131622
Cell Stem Cell. 2019 Dec 5;25(6):855-870.e11
pubmed: 31786016
Biol Direct. 2020 Oct 14;15(1):18
pubmed: 33054808
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Cell Metab. 2013 Nov 5;18(5):698-711
pubmed: 24206664
Cell Death Dis. 2019 Oct 17;10(11):786
pubmed: 31624245
Mol Cancer Res. 2018 Apr;16(4):682-695
pubmed: 29453322
Cancer Cell. 2012 Nov 13;22(5):631-44
pubmed: 23153536
Cell Tissue Res. 2018 May;372(2):269-275
pubmed: 29032465
Nature. 2008 Oct 16;455(7215):930-5
pubmed: 18724359
Cold Spring Harb Perspect Med. 2013 Oct 01;3(10):a014415
pubmed: 24086065
Cancer Res. 2021 Apr 1;81(7):1627-1632
pubmed: 33509943
Curr Opin Pediatr. 2005 Feb;17(1):7-13
pubmed: 15659956
Cell. 2013 May 23;153(5):1149-63
pubmed: 23664763
Cell Tissue Res. 2018 May;372(2):195-209
pubmed: 29572647
Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366581
Biochim Biophys Acta. 2015 Jul;1849(7):845-60
pubmed: 25464034
Nat Cell Biol. 2019 Jul;21(7):889-899
pubmed: 31263264
Front Oncol. 2020 Aug 19;10:1411
pubmed: 32974147
BMC Res Notes. 2008 Oct 28;1:95
pubmed: 18957096
Cell Metab. 2008 Mar;7(3):269-76
pubmed: 18316032
Nature. 2008 Oct 16;455(7215):971-4
pubmed: 18923524
Oncogene. 2016 Sep 8;35(36):4675-88
pubmed: 26829052
Nat Biotechnol. 2014 Sep;32(9):903-14
pubmed: 25150838
Front Oncol. 2021 Feb 03;10:625332
pubmed: 33614505
Oncol Rep. 2012 Jul;28(1):186-92
pubmed: 22576801
Cancer Lett. 2010 Jul 28;293(2):144-57
pubmed: 20153925
Pediatr Blood Cancer. 2018 Oct;65(10):e27257
pubmed: 29797634
Cancer Res. 2010 Apr 1;70(7):2749-58
pubmed: 20233875
Nature. 2008 Oct 16;455(7215):967-70
pubmed: 18923523
Sci Rep. 2020 Apr 28;10(1):7157
pubmed: 32346009
Prostate. 2006 Aug 1;66(11):1203-12
pubmed: 16652388
Oncotarget. 2016 Feb 23;7(8):8726-42
pubmed: 26646586
Cancer Res. 2009 Oct 1;69(19):7803-10
pubmed: 19773438
Pediatr Blood Cancer. 2011 Apr;56(4):578-83
pubmed: 21298742
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Cancer Discov. 2018 May;8(5):582-599
pubmed: 29510988
Nat Genet. 2018 Apr;50(4):515-523
pubmed: 29379199
EMBO J. 1997 Jun 2;16(11):2985-95
pubmed: 9214616
J Pathol. 2015 Jan;235(1):90-100
pubmed: 25142020
Mol Cell. 2007 Nov 9;28(3):501-12
pubmed: 17996713
J Clin Oncol. 2011 Aug 20;29(24):3286-92
pubmed: 21768459
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7356-7361
pubmed: 29941555
Int J Oncol. 2013 Feb;42(2):609-16
pubmed: 23232578
Int J Cancer. 2013 Feb 1;132(3):E106-15
pubmed: 22907398
Oncotarget. 2016 Jun 14;7(24):36293-36310
pubmed: 27167114
EMBO J. 2001 Mar 15;20(6):1383-93
pubmed: 11250904
Cell Death Dis. 2013 Apr 11;4:e586
pubmed: 23579273
Science. 2010 May 28;328(5982):1172-6
pubmed: 20508131
Science. 2018 Dec 7;362(6419):1165-1170
pubmed: 30523111
Cancer Res. 2007 Aug 15;67(16):7551-5
pubmed: 17699757
iScience. 2019 Nov 22;21:188-204
pubmed: 31670074
Cancer Res. 2019 Apr 1;79(7):1438-1450
pubmed: 30894372
Oncogene. 2021 Sep;40(38):5741-5751
pubmed: 34333551
Mol Cancer Res. 2013 Jan;11(1):54-61
pubmed: 23175522
Cell Death Dis. 2018 Jan 25;9(2):115
pubmed: 29371595
Children (Basel). 2019 Jan 17;6(1):
pubmed: 30658459
PLoS One. 2015 Feb 06;10(2):e0117493
pubmed: 25658620